Target intelligence / Profile preview

MicroRNA 3689d-2 (MIR3689D2)

Target
MIR3689D2
Molecular classification
MicroRNA, Non-coding RNA, Other (RNA gene, not coding for a protein)
01

Overview

MicroRNA 3689d-2 (MIR3689D2) is a small, non-coding RNA found in humans, transcribed from the MIR3689D2 gene. Like other microRNAs, it is processed by the Drosha and Dicer enzymes into a mature microRNA, which is then incorporated into the RNA-induced silencing complex (RISC). The mature molecule recognizes partially complementary sequences in target mRNAs, most commonly resulting in translational inhibition or destabilization of the target mRNA. Specific SNPs in the MIR3689D2 gene have been associated with altered secondary structure and reduced miRNA production, contributing to increased expression of genes involved in the MAPK/Ras signaling pathway and increased susceptibility to B-cell acute lymphoblastic leukemia (B-ALL). There are currently no known drugs or approved therapeutics specifically targeting MIR3689D2. Research into its disease associations focuses primarily on its role as a risk marker and regulator of key oncogenic pathways.

Other names
MIR3689D2hsa-mir-3689d-2
02

Mechanism of action

Not applicable for drugs, as no direct drugs identified; generally, drugs or interventions that modulate miRNAs act by inhibiting or mimicking the mature microRNA, thereby altering the levels of target mRNA expression

03

Biological functions

Post-transcriptional gene regulationModulation of mRNA stability and translationPotential influence on cell differentiation, proliferation, apoptosis, and intracellular signaling (functions general to miRNAs)
04

Disease associations

Cancer (alterations in MIR3689D2 may be involved in cancer risk, particularly B-cell acute lymphoblastic leukemia (B-ALL))Potential marker for B-ALL susceptibility, based on associated SNPsOther disease roles are unknown due to lack of targeted research on MIR3689D2 specifically, but deregulation of miRNAs in general is implicated in a broad range of diseases (notably cancer, neurological, and cardiovascular diseases)
05

Safety considerations

None specifically identified for MIR3689D2; therapeutic challenges and safety issues for microRNA-directed therapies commonly include off-target effects, delivery to intended cells/tissues, and potential disruption of regulation of multiple targets
06

Interacting drugs

None identified in available sources; no drugs currently directly target MIR3689D2
07

Biomarkers

rs62571442 (SNP in MIR3689D2 has been identified as a potential biomarker for B-ALL susceptibility)

Beyond the preview

Go deeper on MicroRNA 3689d-2 (MIR3689D2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on MicroRNA 3689d-2 (MIR3689D2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call